摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[(1-oxopropyl)phenylamino]-1-piperidineacetic acid, methyl ester | 132875-43-5

中文名称
——
中文别名
——
英文名称
4-[(1-oxopropyl)phenylamino]-1-piperidineacetic acid, methyl ester
英文别名
4-[(1-oxopropyl)phenylamino]-1-piperidineacetic acid,methyl ester;methyl 2-[4-(N-propanoylanilino)piperidin-1-yl]acetate
4-[(1-oxopropyl)phenylamino]-1-piperidineacetic acid, methyl ester化学式
CAS
132875-43-5
化学式
C17H24N2O3
mdl
——
分子量
304.389
InChiKey
UBKCQRCHCCIVHO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    22
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    49.8
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    N-苯基-N-(4-哌啶)丙胺 混合盐酸溴乙酸甲酯potassium carbonate 作用下, 以 乙腈 为溶剂, 以53%的产率得到4-[(1-oxopropyl)phenylamino]-1-piperidineacetic acid, methyl ester
    参考文献:
    名称:
    N-phenyl-N-(4-piperidinyl)amides useful as analgesics
    摘要:
    披露了具有通式(I)的N-苯基-N-(4-哌啶基)酰胺衍生物:##STR1## 其中X是从羟基氧羰基较低烷基,较低烷基羰氧较低烷基,烯氧羟基氧羰基较低烷基和(C.sub.1-2)烷氧(C.sub.1-2)-烷氧羰基较低烷基中选择的成员,而Ar,R,R.sup.1和R.sup.2在此定义,包括其同分异构体和酸加成盐。这些化合物表现出相对短的镇痛作用持续时间的镇痛活性。该发明涵盖化合物(I),化合物(I)的制药组合物以及使用(I)提供镇痛的方法。还包括用于制备(I)的某些新型中间体。
    公开号:
    US05019583A1
点击查看最新优质反应信息

文献信息

  • N-phenyl-N-(4-piperidinyl)amides useful as analgesics
    申请人:Glaxo Inc.
    公开号:US05019583A1
    公开(公告)日:1991-05-28
    N-Phenyl-N-(4-piperdinyl)amide derivatives are disclosed having the general formula (I): ##STR1## wherein X is a member selected from the group consisting of alkoxy-carbonyl-lower alkyl, lower alkyl-carbonyloxy-lower alkyl, alkenyloxy-carbonyl-lower alkyl, and (C.sub.1-2)alkoxy-(C.sub.1-2)-alkoxy-carbonyl-lower alkyl, and Ar, R, R.sup.1 and R.sup.2 are defined hereinafter, including isomeric forms thereof and acid addition salts thereof. The compounds exhibit analgesic activity having relatively short durations of analgesic action. The invention embraces the compounds (I), pharmaceutical compositions of (I) and methods of providing analgesia with (I). Also included are certain novel intermediates for making (I).
    披露了具有通式(I)的N-苯基-N-(4-哌啶基)酰胺衍生物:##STR1## 其中X是从羟基氧羰基较低烷基,较低烷基羰氧较低烷基,烯氧羟基氧羰基较低烷基和(C.sub.1-2)烷氧(C.sub.1-2)-烷氧羰基较低烷基中选择的成员,而Ar,R,R.sup.1和R.sup.2在此定义,包括其同分异构体和酸加成盐。这些化合物表现出相对短的镇痛作用持续时间的镇痛活性。该发明涵盖化合物(I),化合物(I)的制药组合物以及使用(I)提供镇痛的方法。还包括用于制备(I)的某些新型中间体。
  • Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgesics
    作者:Paul L. Feldman、Michael K. James、Marcus F. Brackeen、Joanne M. Bilotta、Suzanne V. Schuster、Avis P. Lahey、Michael W. Lutz、M. Ross Johnson、H. Jeff Leighton
    DOI:10.1021/jm00111a041
    日期:1991.7
    In an effort to discover a potent ultrashort-acting mu-opioid analgetic that is capable of metabolizing to an inactive species independent of hepatic function, several classes of 4-anilidopiperidine analgetics were synthesized and evaluated. One series of compounds displayed potent mu-opioid agonist activity with a high degree of analgesic efficacy and an ultrashort to long duration of action. These analgetics, 4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinepropanoic acid alkyl esters, were evaluated in vitro in the guinea pig ileum for mu-opioid activity, in vivo in the rat tail withdrawal assay for analgesic efficacy and duration of action, and in vitro in human whole blood for their ability to be metabolized in blood. Compounds in this series were all shown to be potent mu-agonists in vitro, but depending upon the alkyl ester substitution the potency and duration of action in vivo varied substantially. The discrepancies between the in vitro and in vivo activities and variations in duration of action are probably due to different rates of ester hydrolysis by blood esterase(s). The SAR with respect to analgesic activity and duration of action as a function of the various esters synthesized is discussed. It was also demonstrated that the duration of action for the ultrashort-acting analgetic, 8, does not change upon prolonged infusion or administration of multiple bolus injections.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物